| Autor: |
Papaetis GS; Internal Medicine and Diabetes Clinic, Paphos, Cyprus.; CDA College, Paphos, Cyprus., Kyriacou A; CEDM Centre of Endocrinology, Diabetes & Metabolism, Limassol, Cyprus.; Department of Diabetes, Endocrinology & Obesity Medicine, Salford Royal NHS Foundation Trust, United Kingdom. |
| Jazyk: |
angličtina |
| Zdroj: |
Advances in clinical and experimental medicine : official organ Wroclaw Medical University [Adv Clin Exp Med] 2022 Nov; Vol. 31 (11), pp. 1265-1274. |
| DOI: |
10.17219/acem/151695 |
| Abstrakt: |
Polycystic ovary syndrome (PCOS) is a disorder that involves several organ systems and cellular pathways. It is strongly influenced by environmental and epigenetic factors. The principal goal of all therapeutic approaches to individuals with reproductive abnormalities is the treatment of subfertility or the regulation of menstruation when pregnancy is not desired. Obesity is closely related to insulin resistance (IR) and subsequent hyperinsulinemia, which aggravate hyperandrogenism and impair early follicle development. Weight loss is of vital importance for overweight/obese individuals with anovulatory infertility. The GLP-1R agonists have achieved remarkable weight reduction and abdominal fat loss in patients with type 2 diabetes (T2D), as well as in overweight/obese individuals and individuals with prediabetes. They have also been shown to promote lower fasting insulin levels and insulin resistance markers. These beneficial effects have been suggested to be particularly helpful in women with PCOS, while their possible role in the hypothalamic-pituitary-gonadal axis is under intense research. This review analyzes the current evidence for GLP-1R agonists, focusing on their effects on ovarian morphology, menstrual dysfunction and fertility outcomes. It also discusses their future role in achieving targeted therapeutic approaches. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
